Frederick G. Vogt, Ph.D., J.D.

Frederick G. Vogt, Ph.D., J.D.

Interim Chief Executive Officer and President, General CounselatIovance Biotherapeutics· In proxies 2021–2025

Pay in FY2025-83% from the year before · Iovance Biotherapeutics stock -63.1% the same year

Frederick G. Vogt, Ph.D., J.D. was paid $1.9M in FY2025 (Dec), down 83%. Iovance Biotherapeutics stock fell 63.1% that year.

Pay$100 in the stock at the end of FY20 → $6
Pay is from the Summary Compensation Table of each Iovance Biotherapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Iovance BiotherapeuticsPublic company · 5 yr
    • Interim Chief Executive Officer and President, General Counsel2021 – Present · 5 yrStock in role -70%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?